Roche Signs a License Agreement with Shape to Advance AAV-based RNA Editing Technology for Neuroscience and Rare Disease
Shots:
- Shape is eligible to receive $3B+ including initial payment- development- regulatory- and sales milestone along with royalties on sales of therapies resulting from the collaboration
- The collaboration will utilize Shape’s RNA editing platform i.e.- RNAfix and AAVid for next-generation tissue-specific AAVs to develop gene therapy for AD- PD & rare diseases
- Shape to conduct preclinical research to identify & deliver development candidates discovered by RNAfix and AAVid AI-powered platforms. Roche will lead the development & global commercialization of any potential products that emerge from the collaboration
Ref: Globe Newswire | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com